Cerenkov radiation shining a light for cancer theranostics

Teng, Minglei; Liang, Xiaoliu; Liu, Hui; Li, Zhenjie; Gao, Xing; Zhang, Chi; Cheng, Hongwei; Chen, Hu; Liu, Gang

doi:10.1016/j.nantod.2024.102174

Nano Today

2024

DOI: 10.1016/j.nantod.2024.102174

|View full text |Cite

Cerenkov radiation shining a light for cancer theranostics

Minglei Teng,

Xiaoliu Liang,

Hui Liu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Sequentially Dual-Targeted Molecular Theranostic Probe for Radionuclide and Anti-Hypoxic Activatable Photodynamic Therapy of Cancer

Gu,

Zhang,

Chen

et al. 2024

ACS Materials Lett.

View full text Add to dashboard Cite

Type I photodynamic therapy (PDT), which utilizes type I photoreactions and is less O 2 -dependent, is expected to exert ideal synergistic therapy performance when combined with targeted radionuclide therapy (TRT). However, this combination has been less explored. To achieve it, this study presents a sequentially dual-targeted molecular theranostic probe for combining TRT and antihypoxic activatable PDT against prostate cancer. The probe achieves prostatespecific membrane antigen (PSMA)-mediated lock-and-key targeting ability and monoamine oxidase A (MAO-A) hydrolysis with activated fluoro-photoacoustic signals and O 2•− generation. The PSMA motif not only enhances the targeting specificity but also increases the intracellular accumulation capacity of probe and promotes more MAO-A activation. In this regard, an enhanced inhibition of tumor growth is obtained for combined activatable antihypoxic PDT and TRT in comparison to any single regimen, including the commercial 177 Lu-PSMA-617, thereby demonstrating the effective antitumor effect. This study provides a potential solution for a combination of TRT and PDT for effective tumor therapy.

show abstract

Sequentially Dual-Targeted Molecular Theranostic Probe for Radionuclide and Anti-Hypoxic Activatable Photodynamic Therapy of Cancer

Gu,

Zhang,

Chen

et al. 2024

ACS Materials Lett.

View full text Add to dashboard Cite

show abstract

Nanomaterial-based regulation of redox metabolism for enhancing cancer therapy

Jia,

Wang,

Qiao

et al. 2024

Chem. Soc. Rev.

View full text Add to dashboard Cite

show abstract

Radionuclide-labelled nanoparticles for cancer combination therapy: a review

Sun,

Wang,

Zhang

2024

J Nanobiotechnol

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Cerenkov radiation shining a light for cancer theranostics

Cited by 3 publications

References 130 publications

Sequentially Dual-Targeted Molecular Theranostic Probe for Radionuclide and Anti-Hypoxic Activatable Photodynamic Therapy of Cancer

Sequentially Dual-Targeted Molecular Theranostic Probe for Radionuclide and Anti-Hypoxic Activatable Photodynamic Therapy of Cancer

Nanomaterial-based regulation of redox metabolism for enhancing cancer therapy

Radionuclide-labelled nanoparticles for cancer combination therapy: a review

Contact Info

Product

Resources

About